Three year study ahead for Baxter's Gammagard in Alzheimer's disease
This article was originally published in Scrip
Executive Summary
Baxter International is to start a second Phase III trial later this quarter of its immune globulin infusion product Gammagard Liquid in Alzheimer's disease after a first Phase III study passed a futility analysis.